Liposomal curcumin inhibits hypoxia-induced angiogenesis after transcatheter arterial embolization in VX2 rabbit liver tumors

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 2601-2611

  Dai, Feng ^a,b   Zhang, Xiuming ^a   Shen, Wenrong ^a   Chen, Jun ^a   Liu, Liucheng ^a   Gao, Gejun ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

Angiogenesis; Embolization; Hypoxia inducible factor 1 ; Liver tumor

Indexed keywords

ANTINEOPLASTIC AGENT; COLORING AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINATED POPPYSEED OIL; LIPOSOMAL CURCUMIN; MESSENGER RNA; POLYVINYL ALCOHOL; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CAPILLARY DENSITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG FORMULATION; HYPOXIA; LIVER TUMOR; NEW ZEALAND WHITE (RABBIT); NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; SURFACE PROPERTY; TUMOR VASCULARIZATION; TUMOR VOLUME; ZETA POTENTIAL;

EID: 84941670838     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S87931     Document Type: Article

References (27)

1. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors and screening. Semin Liver Dis. 2005;25(2):143–154.
2. Lllovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.
3. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–977.
4. Brown DB, Gould JE, Gervais DA, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2007;18(12):1469–1478.
5. Llovet JM, Real MI, Montaña X, et al; Barcelona Liver Cancer Group. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359(9319):1734–1739.
6. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002;8(4):62–67.
7. Virmani S, Rhee TK, Ryu RK, Sato KT, Lewandowski RJ. Comparison of hypoxia-inducible factor-1 alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J Vasc Inter Radiol. 2008;19(10):1483–1489.
8. Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia-inducible factor 1 alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal mode l. Cardivasc Intervent Radiol. 2010;33(4):806–812.
9. Shahneh FZ, Baradaran B, Zamani F, Aghebati-Maleki L. Tumor angiogenesis and anti-angiogenic therapies. Hum Antibodies. 2013;22(1–2): 15–19.
10. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7(6): 475–485.
11. Jia ZZ, Jiang GM, Feng YL. Serum HIF-1 alpha and VEGF levels pre- and post-TACE in patients with primary liver cancer. Chin Med Sci J. 2011;26(3):158–162.
12. Bae MK, Kim SH, Jeong JW, et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006;15(6): 1557–1562.
13. Shehzad A, Lee J, Lee YS. Curcumin in various cancer. Biofactors. 2013;39(1):56–68.
14. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104(6):1322–1331.
15. Chen C, Johnston TD, Jeon H, et al. An in vitro study of liposomal curcumin: stability, toxicity and biological activity in human lymphocytes and Epstein-Barr virus-transformed human B-cells. Int J Pharm. 2009;366(1–2):133–139.
16. Moreira PL, An YH. Animal models for therapeutic embolization. Cardiovasc Intervent Radiol. 2003;26(2):100–110.
17. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 in common human cancers and their metastases. Caner Res. 1999;59(22):5830–5835.
18. Yamaguchi R, Yano H, Lemura A, Ogasawara S, Haramaki M, Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 1998;28(1):68–77.
19. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.
20. Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014;7:1927–1932.
21. Yadaw VR, Aqqarwal BB. Curcumin: a component of the golden spice, targets multiple angiogenic pathways. Cancer Biol Ther. 2011;11(2): 236–241.
22. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol. 2007;595:185–195.
23. Shan B, Schaaf C, Schmidt A, et al. Curcumin suppresess HIF1A synthesis and VEGF release in pituitary adenomas. J Endocrinol. 2012; 214(3):389–398.
24. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 2007;6(4):1276–1282.
25. Mach CM, Mathew L, Mosley SA, Kurzrock R, Smith JA. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res. 2009;29(6):1895–1899.
26. Martin R, Geller D, Espat J, et al. Safety and efficacy of transarterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology. 2012;59(113):255–260.
27. Rhee TK, Young JY, Larson AC, et al. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1 alpha in rabbit VX2 liver tumor. J Vasc Interv Radiol. 2007;18(5):639–645.